Development asset linked to Perspective Therapeutics in public FDA and regional records.
pharma · Pancreatic Ductal Adenocarcinoma · Neuroendocrine Tumor Grade 2 · CATX
Perspective Therapeutics
Perspective Therapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Seattle, USA HQ
2023 Founded
144 Employees
Public company Type
CATX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Seattle, USA
- Founded
- 2023
- Employees
- 144
- Programs
- 6
- Drugs
- 1
- Patents
- 1
Perspective Therapeutics pipeline
Portfolio lens on 1 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Perspective Therapeutics drug portfolio — 1 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.